Cabot Corporation (NYSE: CBT) is a leading global specialty chemical and performance materials company headquartered in Boston, Massachusetts. We deliver performance solutions that solve customers'​ challenges today and prepare them to meet tomorrow's needs.

About us With more than 65 years of experience in delivering life-changing science, Lantheus is committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease. Lantheus is headquartered in Massachusetts and has offices in New Jersey, Canada and Sweden.

Established in the mid 1970's, New England Biolabs, Inc. (NEB) is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, synthetic biology, glycobiology, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors, including the development of molecular diagnostics, as well as nucleic acid vaccines. New England Biolabs is a privately held company, headquartered in Ipswich, MA, and has extensive worldwide distribution through a network of exclusive distributors, agents and subsidiaries located in Australia, Canada, China, France, Germany, Japan, New Zealand, Singapore, South Korea and the UK. For more information about New England Biolabs visit www.neb.com. We welcome you to our Linkedin community and we ask that you please follow our community guidelines, you can find them here: http://nebiolabs.com/community Visit us on Youtube for protocol and product videos: youtube.com/nebiolabs Follow us on Twitter: twitter.com/#!/nebiolabs

LGC is a leading, global life science tools company, providing mission-critical components and solutions into high-growth application areas across the human healthcare and applied market segments. Its high quality product portfolio is comprised of mission-critical tools for genomic analysis and for quality assurance applications, which are typically embedded and recurring within our customers’ products and workflows and are valued for their performance, quality and range. LGC’s tools play a key role in customer workflows from discovery applications through to commercial manufacture and enable its customers to: bring new diagnostics and therapies to market; progress research and development; optimise food production; and continuously monitor and enhance the quality of food, the environment and consumer products. LGC’s 175+ years of scientific heritage, combined with a track record of innovation and value-enhancing acquisitions, has enabled the company to build its product portfolio and expertise, and develop deep relationships with customers, industry partners and the global scientific community. LGC’s core purpose of Science for a safer world and its core values of passion, curiosity, integrity, brilliance and respect, drive its culture. As of 30 June 2021, it employs 4,350 employees, of which over 1,175 employees hold PhD and/or master’s degrees. Its products and services are delivered by highly qualified and experienced teams, operating from a global network of accredited sites that showcase its scientific and manufacturing capabilities.

Cambridge Isotope Laboratories, Inc. (CIL) is the world leader in the separation and manufacture of stable isotopes and stable isotope-labeled compounds. With approximately 700 employees and laboratories in five countries, CIL specializes in the process of labeling biochemical and organic compounds with highly enriched, stable (non-radioactive) isotopes of carbon, hydrogen, nitrogen and oxygen. Our chemists substitute a common atom for a rare, highly valued isotopic component so that the final product can be readily measured or traced using mass spectrometry (mass spec) or nuclear magnetic resonance (NMR). CIL¹s products are utilized in laboratories, medical, government and academic research centers and health care facilities worldwide. We are proud that CIL products have contributed to medical advancements in cancer research, new drug development, environmental analysis, genomics and proteomics and medical diagnostic research. CIL¹s vision began when it was founded in 1981 by Dr. Joel Bradley, an organic chemist from MIT. We now produce more than 15,000 products and have ISO 13485 quality systems, as well as cGMP production capabilities. The CIL group is comprised of six companies: Cambridge Isotope Laboratories, Inc. (CIL), CIL Isotope Separations (CIS), CIL Canada, Inc. in Montreal, Canada; Euriso-Top in Saclay, France; ABX GmbH in Dresden, Germany and CIL China.

ICP Building Solutions is the foremost supplier of professional products and solutions for building envelope, cementitious and sports surface needs. Comprising dozens of industry-leading brands across numerous industries and applications, ICP offers the industry’s most comprehensive portfolios to building professionals all over the globe, all backed by its exclusive Masterworks training and education program.

At Worthen Industries we specialize in sustainable solutions by applying technology and a customer-first approach to every challenge. The result isn’t just an industry-leading product. It’s a solution that ensures your processes, product quality, efficiency and environmental practices are optimized. We believe the future is worth doing right.

Sirtex Medical is a global healthcare business with offices in the U.S., Australia, Germany and Singapore, working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres® Y-90 resin microspheres. More than 100,000 doses have been supplied to treat patients with liver cancer at more than 1,300 medical centers in over 50 countries. Together the team at Sirtex is introducing innovative new therapies that promise to improve the lives of people around the world facing the challenges of cancer. Our ongoing success is based on our commitment to serving our medical customers, professionalism, a collaborative working culture, an entrepreneurial spirit, continuous improvement and innovation. We are dedicated to making Sirtex a great place to work and providing all our employees with a range of benefits, programs and services to ensure they have the opportunity to contribute to the success of our business and further their professional careers. We are an equal opportunity employer. For more information, visit www.sirtex.com and connect with us on Twitter and Facebook. SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd.

Stahl specialises in quality coatings for leather and performance coatings, as well as chemicals and dyes for leather processing.

AstenJohnson is a global manufacturer of pulp & paper machine clothing, filaments, technical Advanced Fabrics®, and nonwovens fabrics for filtration, automotive, healthcare, cured-in-place piping and composites. The company has manufacturing facilities in Europe, Asia and North America, with corporate headquarters in Charleston, South Carolina. AstenJohnson emphasizes quality in its innovative products and builds long-term relationships with its customers, associates, suppliers and communities based on five values: Safety, Excellence, Integrity, People, and Sustainability. Together, these values contribute to customer satisfaction.

Replimune's mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response. Replimune is pioneering the development of novel oncolytic immunotherapies. We imagine a world where cancer is a curable disease.

scPharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that, through our proprietary platform, are designed to enable the subcutaneous administration of therapies previously limited to intravenous (IV) delivery—with the goal of transforming infused therapies, advancing patient care, and reducing healthcare costs.